11:41 AM EST - Helix BioPharma Corp. : Announced that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration has accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin. Helix BioPharma Corp.
shares T.HBP are trading down $0.07 at $1.55.
